Odyssey Capital Advisors Inc. Buys Shares of 3,233 Astrazeneca Plc $AZN

Odyssey Capital Advisors Inc. bought a new stake in Astrazeneca Plc (NYSE:AZN) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 3,233 shares of the company’s stock, valued at approximately $567,000.

Other large investors have also recently bought and sold shares of the company. Bangor Savings Bank increased its stake in Astrazeneca by 102.7% in the fourth quarter. Bangor Savings Bank now owns 304 shares of the company’s stock valued at $28,000 after purchasing an additional 154 shares in the last quarter. Eagle Bay Advisors LLC bought a new stake in Astrazeneca in the fourth quarter valued at approximately $30,000. Triumph Capital Management bought a new stake in Astrazeneca in the third quarter valued at approximately $25,000. YANKCOM Partnership bought a new stake in Astrazeneca in the fourth quarter valued at approximately $31,000. Finally, TFC Financial Management Inc. increased its stake in Astrazeneca by 3,350.0% in the fourth quarter. TFC Financial Management Inc. now owns 345 shares of the company’s stock valued at $32,000 after purchasing an additional 335 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on AZN. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Astrazeneca in a research note on Thursday, April 30th. Wall Street Zen raised shares of Astrazeneca from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Citigroup assumed coverage on shares of Astrazeneca in a research report on Tuesday, January 27th. They set a “buy” rating for the company. Morgan Stanley reissued an “overweight” rating on shares of Astrazeneca in a research report on Wednesday, April 8th. Finally, UBS Group reissued a “buy” rating on shares of Astrazeneca in a research report on Friday, April 10th. Twelve equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Astrazeneca has a consensus rating of “Moderate Buy” and an average target price of $205.33.

Astrazeneca Stock Up 0.0%

Shares of AZN stock opened at $181.62 on Monday. The firm has a fifty day moving average of $192.38 and a 200-day moving average of $182.16. The company has a quick ratio of 0.71, a current ratio of 0.91 and a debt-to-equity ratio of 0.52. Astrazeneca Plc has a 12-month low of $136.16 and a 12-month high of $212.71. The company has a market capitalization of $281.67 billion, a price-to-earnings ratio of 27.27, a P/E/G ratio of 1.49 and a beta of 0.26.

Astrazeneca (NYSE:AZN) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.52 by $0.06. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. The company had revenue of $15.29 billion during the quarter, compared to the consensus estimate of $14.93 billion. As a group, equities research analysts predict that Astrazeneca Plc will post 10.26 earnings per share for the current fiscal year.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.